Market Place
Sourcing Support
Natera Initiates EDEN Study For Early Preeclampsia Risk
06 Feb 2026 //
BUSINESSWIRE
Natera Submits Signatera CDx PMA to FDA
02 Feb 2026 //
BUSINESSWIRE
Natera Completes Enrollment In Randomized ACES-EMB Trial
28 Jan 2026 //
BUSINESSWIRE
Prospera Advances Lung Transplant Care In Landmark Study
26 Jan 2026 //
BUSINESSWIRE
Natera Validates Latitude MRD Test For Colorectal Cancer
21 Jan 2026 //
BUSINESSWIRE
Natera`s Fetal Focus Sgnipt Chosen For Key Presentation At SMFM
20 Jan 2026 //
BUSINESSWIRE
Natera Advance MRD Risk Stratification Using Multimodal AI Models
13 Jan 2026 //
BUSINESSWIRE
Natera, NVIDIA Scale AI for Precision Medicine
12 Jan 2026 //
BUSINESSWIRE
Exelixis, Natera Partner On Zanzalintinib Phase 3 Trial
07 Jan 2026 //
BUSINESSWIRE
Natera Launches 21-Gene Fetal NIPT Test
05 Jan 2026 //
BUSINESSWIRE
Natera Unveils ALTAIR Trial Updates At ASCO GI
05 Jan 2026 //
BUSINESSWIRE
Natera To Present At 44Th J.P. Morgan Healthcare Conference
22 Dec 2025 //
BUSINESSWIRE
Natera Unveils Signatera in CALGB/SWOG CRC Study
18 Dec 2025 //
BUSINESSWIRE
I-SPY 2: Signatera Predicts Early Breast Cancer Recurrence
16 Dec 2025 //
BUSINESSWIRE
Natera Withdraws Appeal in NeoGenomics RaDaR Patent Litigation
15 Dec 2025 //
BUSINESSWIRE
Natera and MEDSIR to Collaborate on the MiRaDoR Trial
12 Dec 2025 //
BUSINESSWIRE
PALLAS Study: Signatera MRD Testing Enhances Prognosis
10 Dec 2025 //
BUSINESSWIRE
Natera Presents Lymphoma Discoveries At ASH Conference
09 Dec 2025 //
BUSINESSWIRE
Natera Acquires Foresight Diagnostics
05 Dec 2025 //
BUSINESSWIRE
Signatera Data In Lymphoma And Multiple Myeloma Revealed
03 Dec 2025 //
BUSINESSWIRE
Natera Unveils Signatera Data from 50K+ Patients at ASCO
02 Dec 2025 //
BUSINESSWIRE
Natera Staff Contribute 1,500+ Hours In Annual Volunteer Month
19 Nov 2025 //
BUSINESSWIRE
Natera Reports Third Quarter 2025 Financial Results
06 Nov 2025 //
BUSINESSWIRE
Natera Expands Fetal Focus NIPT to Include 20 Genes
31 Oct 2025 //
BUSINESSWIRE
Natera To Report Its Third Quarter Results On November 6, 2025
30 Oct 2025 //
BUSINESSWIRE
Natera Reports 22.5% Sensitivity in PROCEED-CRC Adenoma Trial
28 Oct 2025 //
BUSINESSWIRE
IMvigor011 Shows 41% OS Gain In Bladder Cancer Patients
20 Oct 2025 //
BUSINESSWIRE
Natera Named To Fast Company`s Next Big Things In Tech List
16 Oct 2025 //
BUSINESS WIRE
Natera To Showcase 14 Studies At ESMO, Featuring IMvigor011
14 Oct 2025 //
BUSINESSWIRE
Natera Hosts Investor Call On October 23, 2025 For ESMO Findings
13 Oct 2025 //
BUSINESSWIRE
Enrollment Tops 1600 in Natera’s EXPAND Trial of Single Gene NIPT
01 Oct 2025 //
BUSINESSWIRE
Natera Publishes Signatera™ Validation Study In Testicular Cancer
30 Sep 2025 //
BUSINESSWIRE
Court Rules for NeoGenomics in Patent Lawsuit Against Natera
29 Aug 2025 //
PHARMAWEB
Signatera Picked for NRG Ph 3 ARCHER Trial in Bladder Cancer
28 Aug 2025 //
BUSINESSWIRE
Natera To Present Signatera Data At IASLC Lung Cancer Meet
25 Aug 2025 //
BUSINESSWIRE
Natera Introduce AI Model for Diagnostic & Therapeutic Innovation
22 Aug 2025 //
BUSINESSWIRE
Natera Tech Highlighted in 300+ Publications, Medicine Leadership
22 Aug 2025 //
BUSINESSWIRE
IMvigor011 Shows Positive Results, Signatera Predicts Benefit
18 Aug 2025 //
BUSINESSWIRE
Natera`s Q2 2025 Financial Results Released
07 Aug 2025 //
BUSINESSWIRE
Natera Highlights Prospera Data at WTC 2025 With 16 Abstracts
01 Aug 2025 //
BUSINESSWIRE
Natera`s Q2 Results to be Announced on August 7, 2025
31 Jul 2025 //
BUSINESSWIRE
Natera Launches ABCSG 61 `TEODOR` Trial in Breast Cancer
29 Jul 2025 //
BUSINESSWIRE
Natera Highlights Latitude™ MRD in Colorectal Cancer at ESMO
07 Jul 2025 //
BUSINESSWIRE
Natera to Present Signatera Data at ESMO GI Conference
01 Jul 2025 //
BUSINESSWIRE
Natera Announces Medicare Coverage for Signatera Genome
04 Jun 2025 //
BUSINESSWIRE
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
02 Jun 2025 //
BUSINESSWIRE
Natera to Present 25+ Signatera Studies at 2025 ASCO Meeting
22 May 2025 //
BUSINESSWIRE
Signatera Data from I-SPY 2 Trial at ESMO Breast Congress
08 May 2025 //
BUSINESSWIRE
Natera Reports First Quarter 2025 Financial Results
08 May 2025 //
BUSINESSWIRE
Prospera™ Heart Test Outperforms dd-cfDNA in Detecting Rejection
07 May 2025 //
BUSINESSWIRE
Largest Sarcoma Study Shows Signatera`s Excellent Performance
05 May 2025 //
BUSINESSWIRE
Natera to Report its First Quarter Results on May 8, 2025
01 May 2025 //
BUSINESSWIRE
DEFINE-HT: Prospera Heart Outperforms Biopsy in Graft Risk
29 Apr 2025 //
BUSINESSWIRE
Natera Launches Signatera Genome MRD Test
24 Apr 2025 //
BUSINESSWIRE
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
22 Apr 2025 //
BUSINESSWIRE
Natera Enrolls First Patients In HEROES Trial For HER2+ Breast Cancer
10 Mar 2025 //
BUSINESSWIRE
Natera`s Ph 3 CALGB/SWOG 80702 Trial Results In Colorectal Cancer
25 Jan 2025 //
BUSINESSWIRE
Guardant prevails over Natera in false advertising case
26 Nov 2024 //
FIERCE PHARMA
Natera Completes Signatera™ Analysis from CALGB/SWOG 80702 Trial
12 Nov 2024 //
BUSINESSWIRE
Natera To Present New Signatera CRC Data At ESMO
08 Sep 2024 //
BUSINESSWIRE
